METHOD FOR SURGICAL MANAGEMENT OF RECURRENT PTERYGIUM Russian patent published in 2024 - IPC A61F9/07 A61F2/14 A61K35/16 A61P27/02 

FIELD: medicine; ophthalmosurgery.

SUBSTANCE: invention can be used for surgical treatment of recurrent pterygium. That is ensured by preparing the first and second components of the two-component autologous fibrin glue, which are filled in two different sterile syringes with volume of 1 ml. After epibulbar and subconjunctival anesthesia, pterygium head is separated from corneal surface with the help of dissector and excised with scissors to unchanged corneal stroma and sclera. Further, a portion of the limbal zone is cut out in the area of an internal quadrant of pterygium growth with the help of a dosed diamond knife with depth of 350 mcm, width of 2 mm, and a limb length of up to 4 mm, forming a bed for an autograft. Thereafter, in the upper limb quadrant of the same eye, a cornea-conjunctival graft is cut out, corresponding to the size of the excised limb zone in the inner quadrant with width of 2 mm, a limb length of up to 4 mm, using a dosed diamond knife with depth of 350 mcm. Components of the two-component autologous fibrin glue are sequentially instilled into a prepared bed for a cornea-conjunctival autograft in amount of 0.1 ml. After 2-minute exposure, the graft is moved into the prepared bed of the corresponding orientation and repeated sequential instillation of components of two-component autologous fibrin glue on laid corneal-conjunctival autograft. Operation is completed by applying a soft contact lens on the ocular surface.

EFFECT: invention provides an increase in the effectiveness of the surgical treatment of recurrent pterygium by reducing the duration of the surgical intervention, reducing the length of epithelization, minimizing the risk of postoperative inflammation due to living thrombocytes and adhesive molecules included in the two-component autologous fibrin glue, as well as reducing the postoperative discomfort of the patients.

1 cl, 11 dwg, 2 ex